Please login to the form below

Not currently logged in
Email:
Password:

Ovid Therapeutics adds member to scientific advisory board

Dr Jerome Zeldis joins the firm
ovid Therapeutics

New York-based Ovid Therapeutics has appointed Dr Jerome Zeldis to its scientific advisory board.

Ovid is a privately-held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain.

Dr Zeldis has been noted for his successful experience in drug development and previously served as Celgene's senior VP of clinical research and medical affairs.

Prior to joining Celgene in 1997, Dr Zeldis was associate director of clinical research at Sandoz Research Institute and director of medical development at Janssen Pharmaceutical Research Institute.

He said: “Ovid is pursuing an ambitious approach of tackling rare neurological diseases with significant unmet needs. With this goal, the company has assembled a world-class leadership and is employing a science-based approach to target new pathways that are involved in these diseases.

“I look forward to working closely with Ovid's team.”

Jeremy Levin, CEO and chairman of Ovid, added: “We are delighted and privileged to welcome Jerry to our scientific advisory board.

“Jerry's advice and insight will be extremely valuable as we enter the clinic.”

12th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics